bioTheranostics, Inc's Breast Cancer Index, a genomic test quantifying the risk of breast cancer recurrence and predicting which patients will likely benefit from extended endocrine therapy, will be covered by Medicare.
bioTheranostics, Inc’s Breast Cancer Index, a genomic test quantifying the risk of breast cancer recurrence and predicting which patients will likely benefit from extended endocrine therapy, will be covered by Medicare.
The CMS policy will cover use of the test to predict risk of late recurrence in women with early state, estrogen receptor-positive breast cancer, who are concerned about continuing anti-hormonal therapy. The coverage and payment will even be made retrospectively for previously submitted claims, according to bioTheranostics.
“This critical information will allow many women to avoid unnecessary treatment and potential side effects that can adversely affect their health and quality of life,” Nicolas Barthelemy, president and chief executive officer of bioTheranostics, said in a statement. “We appreciate Palmetto GBA’s consideration and diligence in reaching this coverage decision.”
The Breast Cancer Index is currently the only molecular test covered by Medicare that assess an individual patient’s risk of breast cancer recurrence after 5 years, Mr Barthelemy added.
ASCO recently updated its guidelines to encourage consideration of extended endocrine treatment in some breast cancer patients beyond 5 years. However, some women considering extended therapy are concerned about documented toxicity or possible patient-specific side effects.
“Women with breast cancer face difficult tradeoffs between wanting to take steps to help prevent the recurrence of their disease and facing significant side effects and costs related to extended endocrine treatments,” Ruth O’Regan, MD, MRCPI, director of translational breast cancer research at the Winship Cancer Institute of Emory University. “The Breast Cancer Index provides important, patient-specific genomic information that helps clinicians identify patients who may not benefit from extended endocrine treatments, allowing them the choice of discontinuing therapy.”
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen